Molecular Characterization of Circulating Tumor Cells Identifies Predictive Markers for Outcome in Primary, Triple‐Negative Breast Cancer Patients

mRNA profiles of circulating tumor cells were analysed in patients with triple‐negative breast cancer before and after therapy to identify additional treatment options.
[Journal of Cellular and Molecular Medicine]
Full Article
Bookmark

No account yet? Register

0
Share

KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-Negative Breast Cancer Cells by Repressing the EGFR gene

Investigators report that krüppel-like factor 4 was a major determinant of epidermal growth factor receptor expression and activity in TNBC cells.
[Breast Cancer Research]
Full Article
Bookmark

No account yet? Register

0
Share

CRISPR/Cas9 Knockout of Human Arylamine N-Acetyltransferase 1 in MDA-MB-231 Breast Cancer Cells Suggests a Role in Cellular Metabolism

Scientists provided evidence that N-acetyltransferase 1 was not just a xenobiotic metabolizing enzyme and might have a role in endogenous cellular metabolism.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Contrasting DCIS and Invasive Breast Cancer by Subtype Suggests Basal-Like DCIS as Distinct Lesions

Investigators performed subtype stratified analyses and identified key differences between ductal carcinoma in situ and invasive breast cancer that suggested subtype specific progression.
[npj Breast Cancer]
Full Article
Bookmark

No account yet? Register

0
Share

Organoid Models for Mammary Gland Dynamics and Breast Cancer

The authors summarized key aspects of mammary gland biology and corresponding organoid models. The investigators also discussed emerging applications where organoids will be transformative for studying both the biology and diseases of the breast.
[Current Opinion in Cell Biology]
Abstract
Bookmark

No account yet? Register

0
Share

Regulation of Autophagy by Protein Kinase C-ε in Breast Cancer Cells

Reasearchers showed that protein kinase C-ε promoted breast cancer cell survival not only by inhibiting apoptosis but also by inducing autophagy.
[International Journal of Molecular Sciences]
Full Article
Bookmark

No account yet? Register

0
Share

Oncogene PRR14 Promotes Breast Cancer through Activation of pI3K Signal Pathway and Inhibition of CHEK2 Pathway

Investigators showed PRR14 contributed to breast carcinogenesis mainly through overexpression, which derived from elevated transcription and gene amplification.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Antitumor Effect of a WEE1 Inhibitor and Potentiation of Olaparib Sensitivity by DNA Damage Response Modulation in Triple-Negative Breast Cancer

Scientists investigated the antitumor effects of a WEE1 inhibitor and the mechanisms responsible for its effects on the cell cycle and DNA repair pathway as a monotherapy and in combination with a PARP inhibitor, an ATR inhibitor, and a DNA damage-inducing agent in six TNBC cell lines and in a Balb/c athymic nude mouse xenograft model.
[Scientific Reports]
Full Article
Bookmark

No account yet? Register

0
Share

Mitochondrial Dysfunction Generates Aggregates That Resist Lysosomal Degradation in Human Breast Cancer Cells

Researchers demonstrated protein aggregates and autophagy receptors, TAX1BP1 and NDP52, as potential endpoints for monitoring autophagy during drug development and clinical studies.
[Cell Death & Disease]
Full Article
Bookmark

No account yet? Register

0
Share

Rapid Cancer Diagnosis and Early Prognosis of Metastatic Risk Based on Mechanical Invasiveness of Sampled Cells

Investigators evaluated the mechanical invasiveness of established breast and pancreatic cell lines and of tumor-cells from fresh, suspected pancreatic cancer tumors. The mechanical invasiveness matched the in vitro metastatic potential in cell lines as determined with Boyden chamber assays.
[Annals of Biomedical Engineering]
Abstract
Bookmark

No account yet? Register

0
Share

Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

Eli Lilly and Company announced Verzenio® in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free survival, significantly decreasing the risk of breast cancer recurrence or death compared to standard adjuvant endocrine therapy alone.
[Lilly]
Press Release
Bookmark

No account yet? Register

0
Share
Share